April 19, 2022
The Top 10 Market Access Challenges
5 Minute Read
We explore the 10 most common challenges facing Market Access operations, based on over 15 years of experience with more than 250 pharma manufacturers.
Blog
April 11, 2022
Best Price and Copay Challenges: Frequently Asked Questions
11 Minute Read
Common manufacturer concerns on best price calculations, copay accumulators and maximizers, and 340B management as the effective date for the CMS Final Rule approaches.
March 28, 2022
Medicare Part B Sequestration Update
3 Minute Read
Regulatory Market Update Updates for Pharma Manufacturers As always, if you have questions on any of the content found in this or previous market updates, please reach out to...
March 24, 2022
Best Practices: Achieving Your Pre-Launch Sales Forecasts
6 Minute Read
Market access leaders from DBV Technologies, Karyopharm Therapeutics, and Sesen Bio discuss critical factors in a successful launch and ways to achieve pre-launch forecasts.
March 7, 2022
Unifying IntegriChain’s Services & Support: Customer Support and Value Realization
4 Minute Read
In his second unification-focused blog, President and COO Josh Halpern discusses IntegriChain's investment in customer support to better augment the value for customers and end-users.
February 28, 2022
Overcoming Drug Commercialization Challenges in Rare Disease
5 Minute Read
Solutions to common challenges that manufacturers face when commercializing rare and orphan disease therapies.
February 24, 2022
Branded Pharma Fee: Manufacturer Considerations
5 Minute Read
And other regulatory updates on Line Extension guidance, the upcoming DUNS number transition, and emergency 340B flexibilities.
February 15, 2022
Unifying IntegriChain’s Services & Support: Data Management
4 Minute Read
President and COO Josh Halpern discusses the current and future capabilities of the integrated applications, analytics, and datastores within the ICyte Platform.
February 3, 2022
Forecasting for the Future
2 Minute Read
How manufacturers can leverage successful returns and inventory pipeline reserve methodologies for long-term benefits.